Hayano Koichi, Fuentes-Orrego Jorge M, Sahani Dushyant V
Koichi Hayano, Jorge M Fuentes-Orrego, Dushyant V Sahani, Division of Abdominal Imaging and Intervention, Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, United States.
World J Gastroenterol. 2014 Mar 28;20(12):3059-68. doi: 10.3748/wjg.v20.i12.3059.
With the increasing clinical use of cytostatic and novel biologic targeted agents, conventional morphologic tumor burden assessments, including World Health Organization criteria and Response Evaluation Criteria in Solid Tumors, are confronting limitations because of their difficulties in distinguishing viable tumor from necrotic or fibrotic tissue. Therefore, the investigation for reliable quantitative biomarkers of therapeutic response such as metabolic imaging or functional imaging has been desired. In this review, we will discuss the conventional and new approaches to assess tumor burden. Since targeted therapy or locoregional therapies can induce biological changes much earlier than morphological changes, these functional tumor burden analyses are very promising. However, some of them have not gone thorough all steps for standardization and validation. Nevertheless, these new techniques and criteria will play an important role in the cancer management, and provide each patient more tailored therapy.
随着细胞毒性药物和新型生物靶向药物在临床上的使用日益增加，传统的形态学肿瘤负荷评估方法，包括世界卫生组织标准和实体瘤疗效评价标准，正面临着局限性，因为它们难以区分存活肿瘤与坏死或纤维化组织。因此，人们一直期望能找到可靠的治疗反应定量生物标志物，如代谢成像或功能成像。在这篇综述中，我们将讨论评估肿瘤负荷的传统方法和新方法。由于靶向治疗或局部区域治疗可在形态学变化之前更早地诱导生物学变化，这些功能性肿瘤负荷分析非常有前景。然而，其中一些方法尚未完成标准化和验证的所有步骤。尽管如此，这些新技术和标准将在癌症管理中发挥重要作用，并为每位患者提供更具个性化的治疗。
